Published in Future Virol on August 01, 2011
Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol (2012) 1.29
Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity. J Virol (2012) 1.20
The fitness landscape of HIV-1 gag: advanced modeling approaches and validation of model predictions by in vitro testing. PLoS Comput Biol (2014) 1.02
HIV-1 vaccine immunogen design strategies. Virol J (2015) 0.98
Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination. Front Immunol (2012) 0.96
A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. J Transl Med (2015) 0.92
Intersubtype differences in the effect of a rare p24 gag mutation on HIV-1 replicative fitness. J Virol (2012) 0.83
Genetic determinants of Nef-mediated CD4 and HLA class I down-regulation differences between HIV-1 subtypes B and C. Virol J (2015) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med (1997) 12.26
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A (2000) 11.51
Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (1991) 10.85
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science (2002) 9.17
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60
Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A (1997) 8.05
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
The influence of HLA genotype on AIDS. Annu Rev Med (2001) 7.77
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med (2009) 7.33
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity (2007) 6.66
Evolution and transmission of stable CTL escape mutations in HIV infection. Nature (2001) 6.57
Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med (2001) 6.51
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33
Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol (2006) 6.30
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med (2002) 5.17
Toward an AIDS vaccine. Science (2008) 4.83
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol (2007) 4.64
Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med (2004) 4.52
Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol (2009) 4.40
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19
Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature (1994) 3.97
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol (2007) 3.93
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68
HLA and AIDS: a cautionary tale. Trends Mol Med (2001) 3.51
Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med (1999) 3.30
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol (1997) 3.29
Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med (2008) 3.20
Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol (2007) 3.05
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One (2010) 3.02
Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses (1996) 3.01
Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med (2004) 2.99
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81
Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol (2008) 2.72
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol (2010) 2.67
Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS Pathog (2008) 2.59
Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol (2009) 2.51
Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol (2006) 2.48
Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. J Exp Med (2009) 2.39
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol (2008) 2.32
HIV-1 group M conserved elements vaccine. PLoS Pathog (2007) 2.28
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol (2005) 2.24
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One (2009) 2.16
Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope. J Virol (2003) 2.15
HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol (2008) 2.14
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A (2005) 2.10
Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol (2004) 2.09
De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol (2005) 2.04
Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time. AIDS (2005) 1.99
Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. J Virol (2007) 1.98
HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women. AIDS (1999) 1.96
HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol (2008) 1.95
Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57. AIDS (2002) 1.92
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol (2004) 1.91
Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol (2007) 1.89
HIV vaccine failure prompts Merck to halt trial. Nature (2007) 1.87
Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host. J Virol (2006) 1.82
Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol (2010) 1.82
Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS (2006) 1.81
Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J Virol (2010) 1.81
Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol (2010) 1.80
Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol (2005) 1.77
Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Trends Immunol (2006) 1.74
An HIV vaccine--challenges and prospects. N Engl J Med (2008) 1.69
Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J Infect Dis (2009) 1.67
HIV-1 vaccine development after STEP. Annu Rev Med (2010) 1.64
HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently. J Immunol (2006) 1.64
Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog (2010) 1.63
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol (2006) 1.59
Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J Virol (2008) 1.53
The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Nat Med (2010) 1.53
Gradual adaptation of HIV to human host populations: good or bad news? Nat Med (2003) 1.46
Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. J Virol (2011) 1.45
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med (2002) 4.77
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol (2007) 4.64
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55
Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med (2008) 3.48
Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog (2012) 3.35
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol (2008) 2.32
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One (2009) 2.16
TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol (2012) 2.04
HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol (2008) 1.95
Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol (2008) 1.94
Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol (2010) 1.82
Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J Virol (2010) 1.81
Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol (2010) 1.80
Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol (2009) 1.80
Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med (2011) 1.73
Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood (2011) 1.70
Widespread impact of HLA restriction on immune control and escape pathways of HIV-1. J Virol (2012) 1.62
Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol (2007) 1.61
HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology (2008) 1.60
HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J Virol (2009) 1.54
Human leukocyte antigen (HLA) class I down-regulation by human immunodeficiency virus type 1 negative factor (HIV-1 Nef): what might we learn from natural sequence variants? Viruses (2012) 1.48
Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. J Virol (2011) 1.45
A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis (2007) 1.41
Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS (2008) 1.39
Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1. Mol Biol Evol (2009) 1.37
Herpes simplex virus. Front Biosci (2002) 1.32
Transmission and long-term stability of compensated CD8 escape mutations. J Virol (2008) 1.29
Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol (2012) 1.29
Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers. J Acquir Immune Defic Syndr (2011) 1.27
HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis (2005) 1.25
HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem (2010) 1.24
Progression to AIDS in South Africa is associated with both reverting and compensatory viral mutations. PLoS One (2011) 1.24
Maternal transmission of human immunodeficiency virus escape mutations subverts HLA-B57 immunodominance but facilitates viral control in the haploidentical infant. J Virol (2009) 1.22
Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity. J Virol (2012) 1.20
A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. Elife (2013) 1.19
Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences. J Exp Med (2010) 1.19
Frequent and variable cytotoxic-T-lymphocyte escape-associated fitness costs in the human immunodeficiency virus type 1 subtype B Gag proteins. J Virol (2013) 1.14
HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. J Clin Invest (2012) 1.14
Attenuation of multiple Nef functions in HIV-1 elite controllers. Retrovirology (2013) 1.12
Myeloid C3 determines induction of humoral responses to peripheral herpes simplex virus infection. J Immunol (2003) 1.11
A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J Virol (2002) 1.11
HIV evolution in response to HLA-restricted CTL selection pressures: a population-based perspective. Microbes Infect (2008) 1.10
Rapid ex vivo isolation and long-term culture of human Th17 cells. J Immunol Methods (2008) 1.07
Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis (2004) 1.04
Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study. Retrovirology (2009) 1.04
Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res (2008) 1.03
Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes. Retrovirology (2013) 1.01
Aminopeptidase substrate preference affects HIV epitope presentation and predicts immune escape patterns in HIV-infected individuals. J Immunol (2012) 0.98
Quantitative effect of suboptimal codon usage on translational efficiency of mRNA encoding HIV-1 gag in intact T cells. PLoS One (2008) 0.96
HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol (2010) 0.95
Macrophage-derived complement component C4 can restore humoral immunity in C4-deficient mice. J Immunol (2002) 0.94
HLA class I sequence-based typing using DNA recovered from frozen plasma. J Immunol Methods (2012) 0.93
Operationalizing the One Health approach: the global governance challenges. Health Policy Plan (2012) 0.93
Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity. J Virol (2012) 0.93
Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector. Virology (2006) 0.92
Limited immunogenicity of HIV CD8+ T-cell epitopes in acute Clade C virus infection. J Infect Dis (2011) 0.92
Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis (2011) 0.91
Modulation of HIV reservoirs by host HLA: bridging the gap between vaccine and cure. Curr Opin Virol (2012) 0.90
Dynamic range of Nef functions in chronic HIV-1 infection. Virology (2013) 0.89
Host-specific adaptation of HIV-1 subtype B in the Japanese population. J Virol (2014) 0.88
Significant reductions in Gag-protease-mediated HIV-1 replication capacity during the course of the epidemic in Japan. J Virol (2012) 0.88
Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3. J Infect Dis (2005) 0.88
CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. AIDS Res Hum Retroviruses (2008) 0.86
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. PLoS One (2013) 0.86
HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy. AIDS Res Hum Retroviruses (2006) 0.84
Distinct HIV-1 escape patterns selected by cytotoxic T cells with identical epitope specificity. J Virol (2012) 0.84
Intersubtype differences in the effect of a rare p24 gag mutation on HIV-1 replicative fitness. J Virol (2012) 0.83
Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection. Sci Rep (2013) 0.82
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy. Antivir Ther (2003) 0.81
In vitro selection of clinically relevant bevirimat resistance mutations revealed by "deep" sequencing of serially passaged, quasispecies-containing recombinant HIV-1. J Clin Microbiol (2010) 0.81
Impact of antiretroviral therapy duration and intensification on isolated shedding of HIV-1 RNA in semen. J Infect Dis (2013) 0.79
A strong association of human leukocyte antigen-associated Pol and Gag mutations with clinical parameters in HIV-1 subtype A/E infection. AIDS (2016) 0.79
Early immune adaptation in HIV-1 revealed by population-level approaches. Retrovirology (2014) 0.79
HIV-1 Nef and T-cell activation: a history of contradictions. Future Virol (2013) 0.78
Switching and emergence of CTL epitopes in HIV-1 infection. Retrovirology (2014) 0.78
Increasingly successful highly active antiretroviral therapy delays the emergence of new HLA class I-associated escape mutations in HIV-1. Clin Infect Dis (2012) 0.78
Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One (2012) 0.78